Effect of high dose SGLT-2 inhibitor on fatty liver

Effect of high dose SGLT-2 inhibitor on fatty liver - Effect of high dose SGLT-2 inhibitor on fatty liver

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000047270

Enrollment

Registered

2022-03-23

Start date

2021-01-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type2 diabetes/fatty liver

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Diabetic patients whose HbA1C does not improve with regular doses of SGLT-2 inhibitor and who have started higher doses SGLT-2 inhibitor

Exclusion criteria

Exclusion criteria: Patients who have completed less than 6 months of high-dose SGLT-2 inhibitor therapy

Design outcomes

Primary

Measure	Time frame
Compare AST, ALT, FIB-4 index, and NAFLD fibrosis score (NFS) before and after treatment in patients receiving high dose SGLT-2 inhibitor for at least 6 months	—

Countries

Japan

Contacts

Public ContactHironori Konuma

Konuma Internal medicine Gastroenterology Clinic directer

hkonuma.drdr@gmail.com0287375353

Outcome results